Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG)

Vamvakas, Lambros; Matikas, Alexios; Karampeazis, Athanasios; Hatzidaki, Dora; Kakolyris, Stelios; Christophylakis, Charalampos; Boukovinas, Ioannis; Polyzos, Aris; Georgoulias, Vassilis; Souglakos, John

doi:10.1186/1471-2407-14-277

BMC Cancer

Article metrics
Last updated: Sat, 20 Apr 2024 2:24:23 Z

Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG)

Access & Citations

3275

Article Accesses
11

Web of Science
8

CrossRef

Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com